On May 17, 2018, FDA announced approval of Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. According to the agency, Aimovig is the first FDA-approved preventive migraine treatment that works by blocking the activity of calcitonin gene-related peptide, a molecule thatOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.